周五,专注于开发罕见、单基因中枢神经系统疾病基因治疗药物的Passage Bio开盘之初暴涨超33%,此前韦德布什给予公司“跑赢大盘”的评级,并表示对该公司的实验性基因疗法持乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.